Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus SOMOPHYLLIN T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus SOMOPHYLLIN T.
CHOLEDYL SA vs SOMOPHYLLIN-T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/mL. Maximum: 800 mg/day or 400 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal elimination half-life is approximately 8 hours in healthy adults (range 3-13 hours). In neonates, it is prolonged (20-30 h). In smokers, half-life is reduced to 4-5 h. In patients with hepatic cirrhosis or heart failure, half-life may exceed 24 hours.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Approximately 90% is eliminated via hepatic metabolism (primarily via CYP1A2, CYP3A4), and about 10% is excreted unchanged in the urine. Renal clearance accounts for <10% of total clearance in adults. Biliary/fecal excretion is minimal (less than 5%).
Category C
Category C
Bronchodilator
Bronchodilator